Search results for "TOP"

showing 10 items of 17685 documents

Uhlmann number in translational invariant systems

2019

We define the Uhlmann number as an extension of the Chern number, and we use this quantity to describe the topology of 2D translational invariant Fermionic systems at finite temperature. We consider two paradigmatic systems and we study the changes in their topology through the Uhlmann number. Through the linear response theory we linked two geometrical quantities of the system, the mean Uhlmann curvature and the Uhlmann number, to directly measurable physical quantities, i.e. the dynamical susceptibility and to the dynamical conductivity, respectively.

0301 basic medicineSettore FIS/02 - Fisica Teorica Modelli E Metodi MatematiciMathematics::Analysis of PDEsFOS: Physical scienceslcsh:MedicineCurvatureArticleCondensed Matter - Strongly Correlated Electrons03 medical and health sciences0302 clinical medicineTopological insulatorsInvariant (mathematics)lcsh:ScienceCondensed Matter - Statistical MechanicsMathematicsMathematical physicsPhysical quantityQuantum PhysicsMultidisciplinaryChern classStatistical Mechanics (cond-mat.stat-mech)Strongly Correlated Electrons (cond-mat.str-el)lcsh:RUhlmann number Chern number 2D topological Fermionic systems finite temperature dynamical susceptibility dynamical conductivity030104 developmental biologylcsh:QQuantum Physics (quant-ph)Theoretical physicsLinear response theory030217 neurology & neurosurgeryScientific Reports
researchProduct

Anatomy, immunohistochemistry, and numerical distribution of human splenic microvessels.

2019

Abstract The microvascular architecture of the spleen plays an important role in the immunological function of this organ. The different types of vessels are related to different reticular cells each with their own immunomodulatory functions. The present study describes an immunohistochemical and morphometric analysis of the various types of vessels in 21 human autopsy non-pathological splenic samples. On an area of 785,656.37 μm2 for each sample, we classified and quantified the type and number of vascular structures, each according to their morphology and immunohistochemical profile, and obtained the ratios between them. The distribution of trabecular vessels and the characteristics of th…

0301 basic medicineSialic Acid Binding Ig-like Lectin 1CD8 AntigensCD34ImmunoglobulinsSpleenAntigens CD3403 medical and health sciencesMucoproteinsTrabecular veinsReticular cellmedicineHumansAdapaleneVeinForensic PathologySinus (anatomy)VenuleChemistryGeneral MedicineAnatomyImmunohistochemistryActinsPlatelet Endothelial Cell Adhesion Molecule-1Arterioles030104 developmental biologymedicine.anatomical_structureMicrovesselsImmunohistochemistry030101 anatomy & morphologyAutopsyAnatomyCell Adhesion MoleculesSplenic ArterySpleenDevelopmental BiologyAnnals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft
researchProduct

The Sigma-1 Receptor at the Crossroad of Proteostasis, Neurodegeneration, and Autophagy.

2020

Neurodegenerative diseases are linked to dysfunctional proteostasis and disturbed autophagy. Here, we discuss how the sigma-1 receptor (Sig-1R) may act at the intersection of this interaction, as loss-of-function mutations of this unique chaperone are associated with defective autophagy and its pharmacological activation induces autophagic activity.

0301 basic medicineSigma-1 receptorbiologyGeneral NeuroscienceNeurodegenerationAutophagyNeurodegenerative Diseasesmedicine.diseaseCell biology03 medical and health sciences030104 developmental biology0302 clinical medicineProteostasisChaperone (protein)biology.proteinmedicineAutophagyProteostasisHumansReceptors sigmaReceptor030217 neurology & neurosurgeryTrends in neurosciences
researchProduct

Retrieving infinite numbers of patterns in a spin-glass model of immune networks

2013

The similarity between neural and immune networks has been known for decades, but so far we did not understand the mechanism that allows the immune system, unlike associative neural networks, to recall and execute a large number of memorized defense strategies {\em in parallel}. The explanation turns out to lie in the network topology. Neurons interact typically with a large number of other neurons, whereas interactions among lymphocytes in immune networks are very specific, and described by graphs with finite connectivity. In this paper we use replica techniques to solve a statistical mechanical immune network model with `coordinator branches' (T-cells) and `effector branches' (B-cells), a…

0301 basic medicineSimilarity (geometry)Spin glassComputer sciencestatistical mechanicFOS: Physical sciencesGeneral Physics and AstronomyNetwork topologyTopology01 natural sciencesQuantitative Biology::Cell Behavior03 medical and health sciencesCell Behavior (q-bio.CB)0103 physical sciencesattractor neural-networks; statistical mechanics; brain networks; Physics and Astronomy (all)Physics - Biological Physics010306 general physicsAssociative propertybrain networkArtificial neural networkMechanism (biology)ErgodicityDisordered Systems and Neural Networks (cond-mat.dis-nn)Condensed Matter - Disordered Systems and Neural NetworksAcquired immune system030104 developmental biologyBiological Physics (physics.bio-ph)FOS: Biological sciencesattractor neural-networkQuantitative Biology - Cell Behavior
researchProduct

Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.

2017

Abstract Background The epidermal application of the Toll Like Receptor 7 agonist imiquimod and a T-cell peptide epitope (transcutaneous immunization, TCI) mediates systemic peptide-specific cytotoxic T-cell (CTL) responses and leads to tumor protection in a prophylactic tumor setting. However, it does not accomplish memory formation or permanent defiance of tumors in a therapeutic set-up. As a distinct immunologic approach, CTLA-4 blockade augments systemic immune responses and has shown long-lasting effects in preclinical experiments as well as in clinical trials. Objective The study investigates the vaccination capacity of TCI in combination with the checkpoint inhibitor CTLA-4 in matter…

0301 basic medicineSkin NeoplasmsOvalbuminmedicine.medical_treatmentMelanoma Experimentalchemical and pharmacologic phenomenaDermatologyBiochemistryT-Lymphocytes RegulatoryEpitope03 medical and health sciencesMice0302 clinical medicineImmune systemAntineoplastic Agents ImmunologicalAdjuvants ImmunologicmedicineCytotoxic T cellAnimalsHumansCTLA-4 AntigenMolecular BiologyImiquimodMembrane Glycoproteinsbusiness.industryMelanomahemic and immune systemsDrug SynergismTLR7Immunotherapymedicine.diseaseFlow CytometryXenograft Model Antitumor AssaysPeptide FragmentsMice Inbred C57BLCTL*030104 developmental biologyToll-Like Receptor 7CTLA-4030220 oncology & carcinogenesisImmunologyAminoquinolinesImmunotherapybusinessImmunologic MemoryT-Lymphocytes CytotoxicJournal of dermatological science
researchProduct

Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection

2017

Abstract Background Transcutaneous immunization (TCI) is a novel vaccination strategy utilizing the skin associated lymphatic tissue to induce immune responses. TCI using a cytotoxic T lymphocyte (CTL) epitope and the Toll-like receptor 7 (TLR7) agonist imiquimod mounts strong CTL responses by activation and maturation of skin-derived dendritic cells (DCs) and their migration to lymph nodes. However, TCI based on the commercial formulation Aldara only induces transient CTL responses that needs further improvement for the induction of durable therapeutic immune responses. Objective Therefore we aimed to develop a novel imiquimod solid nanoemulsion (IMI-Sol) for TCI with superior vaccination …

0301 basic medicineSkin NeoplasmsT cellImiquimodDermatologyLymphocytic ChoriomeningitisAdministration CutaneousBiochemistryEpitopeMajor Histocompatibility ComplexEpitopesMice03 medical and health sciences0302 clinical medicineImmune systemCell MovementAnimalsHumansLymphocytic choriomeningitis virusMedicineCytotoxic T cellMolecular BiologySkinMice KnockoutImiquimodMembrane Glycoproteinsbusiness.industryVaccinationTLR7Flow CytometryMice Inbred C57BLDisease Models AnimalCTL*030104 developmental biologymedicine.anatomical_structureToll-Like Receptor 7Langerhans Cells030220 oncology & carcinogenesisMyeloid Differentiation Factor 88ImmunologyAminoquinolinesEmulsionsbusinessCD8Signal TransductionT-Lymphocytes Cytotoxicmedicine.drugJournal of Dermatological Science
researchProduct

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placeb…

2018

Summary Background Antiangiogenic therapy has known activity in ovarian cancer. The investigator-initiated randomised phase 2 TRIAS trial assessed the multi-kinase inhibitor sorafenib combined with topotecan and continued as maintenance therapy for platinum-resistant or platinum-refractory ovarian cancer. Methods We did a multicentre, double-blind, placebo-controlled, randomised, phase 2 trial at 20 sites in Germany. Patients (≥18 years) with platinum-resistant ovarian cancer previously treated with two or fewer chemotherapy lines for recurrent disease were stratified (first vs later relapse) in block sizes of four and randomly assigned (1:1) using a web-generated response system to topotec…

0301 basic medicineSorafenibAdultmedicine.medical_specialtyTime FactorsPerforation (oil well)Angiogenesis InhibitorsPlatinum CompoundsNeutropeniaPlaceboGastroenterologyDrug Administration Schedule03 medical and health sciences0302 clinical medicineMaintenance therapyDouble-Blind MethodInternal medicineGermanyAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansProgression-free survivalProtein Kinase InhibitorsAgedOvarian Neoplasmsbusiness.industryMiddle AgedSorafenibmedicine.diseaseProgression-Free Survival030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisDisease ProgressionTopotecanFemaleTopoisomerase I InhibitorsbusinessTopotecanmedicine.drugThe Lancet. Oncology
researchProduct

The role of molecular enrichment on future therapies in hepatocellular carcinoma

2017

Summary Hepatocellular carcinomas (HCCs) are characterised by considerable phenotypic and molecular heterogeneity. Treating HCC and designing clinical trials are particularly challenging because co-existing liver disease, present in most patients, limits aggressive therapeutic options. Positive results in recent phase III clinical trials have confirmed the high value of anti-angiogenic therapies for HCC in both first (sorafenib and lenvatinib) and second line (regorafenib and cabozantinib) treatment modalities. However, failure of several large randomised controlled clinical trials over the last 10 years underlines the necessity for innovative treatment strategies and implementation of tran…

0301 basic medicineSorafenibOncologymedicine.medical_specialtyCarcinoma HepatocellularCabozantinibPhases of clinical research03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineRegorafenibmedicineHumansMolecular Targeted TherapyClinical Trials as TopicHepatologybusiness.industryLiver NeoplasmsPrecision medicinemedicine.diseasedigestive system diseasesClinical trial030104 developmental biologychemistry030220 oncology & carcinogenesisHepatocellular carcinomaImmunotherapybusinessLenvatinibmedicine.drugJournal of Hepatology
researchProduct

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

2020

Proper trial design is critical for the success of clinical investigations. Hepatocellular carcinoma (HCC) is a complex disease that has several unique properties. In 2008, after the approval of sorafenib, a panel of experts proposed guidelines for trial design and endpoints in HCC that have been instrumental during the last decade and provided a framework to allow an homogeneous analysis of reported investigations. Since then, several phase III studies have been reported and novel challenges have emerged. A panel of experts conveyed by AASLD organized a Special Topic Conference on trial design and endpoints to address those emerging challenges. This review summarizes the analysis and concl…

0301 basic medicineSorafenibmedicine.medical_specialtyCarcinoma HepatocellularConsensusEndpoint DeterminationMEDLINEDisease03 medical and health sciences0302 clinical medicinemedicineHumansProgression-free survivalChemoembolization TherapeuticLiquid biopsyIntensive care medicineAdverse effectImmune Checkpoint InhibitorsProtein Kinase InhibitorsClinical Trials as TopicHepatologybusiness.industryLiver NeoplasmsLiquid Biopsymedicine.diseaseLiver TransplantationClinical trial030104 developmental biologyResearch DesignHepatocellular carcinoma030211 gastroenterology & hepatologybusinessmedicine.drugHepatology
researchProduct

A topological look at human trabecular bone tissue

2017

Bone quality is affected by trabecular architecture at microscopic level. Various abnormalities of bone tissue lead to altered strength and to an increased susceptibility to fracture, such as Osteoporosis and Osteoarthritis, two major health burdens of our society. These are two complex musculoskeletal diseases that mainly concern bone tissue. In the last twenty years, there has been a growing interest in finding an appropriate topological model for the micro-architecture of trabecular bone tissue. In particular, we prove that these models involve general topological spaces. The appropriate notion to deal with is that of CW-complex.

0301 basic medicineStatistics and ProbabilityPathologymedicine.medical_specialtyTrabecular bone tissueOsteoporosis030209 endocrinology & metabolismOsteoarthritisTopological spaceBone tissueTopologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineCW-complexBone DensityBone qualityHumansMedicineGeneral Immunology and Microbiologybusiness.industryApplied MathematicsMicroscopic levelGeneral MedicineAnatomyTrabecular architecturemedicine.diseaseTrabecular bone030104 developmental biologymedicine.anatomical_structureModeling and SimulationCW-complex; Euler characteristic; trabecular bone tissue; Kelvin cellCancellous BoneEuler characteristicSettore MAT/03 - GeometriaGeneral Agricultural and Biological SciencesbusinessKelvin cell
researchProduct